Alto Neuroscience (ANRO) News Today → Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free ANRO Stock Alerts $11.96 -0.04 (-0.33%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 1:12 PM | finance.yahoo.comAlto Neuroscience to Present at the Jefferies Global Healthcare ConferenceMay 21, 2024 | businesswire.comAlto Neuroscience Appoints Michael Hanley as Chief Operating OfficerMay 17, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Alto Neuroscience, Inc. Issued By William Blair (NYSE:ANRO)Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Research analysts at William Blair lowered their Q2 2024 earnings per share (EPS) estimates for Alto Neuroscience in a note issued to investors on Wednesday, May 15th. William Blair analyst M. Minter now anticipates that the company will post eaMay 16, 2024 | markets.businessinsider.comBuy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS TreatmentMay 16, 2024 | bloomberg.comAlto Aims to Redefine Psychiatry Landscape: Vanguards of Health CareMay 15, 2024 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Earns "Outperform" Rating from William BlairWilliam Blair restated an "outperform" rating on shares of Alto Neuroscience in a research note on Wednesday.May 14, 2024 | msn.comANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024May 14, 2024 | finance.yahoo.comAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comAlto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesApril 23, 2024 | markets.businessinsider.comTreatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry LandscapeApril 23, 2024 | businesswire.comAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaApril 3, 2024 | finance.yahoo.comAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderApril 2, 2024 | insidertrades.comAlto Neuroscience, Inc. (NYSE:ANRO) CFO Purchases $100,614.00 in StockApril 1, 2024 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) CFO Nicholas Conrad Smith Buys 6,150 SharesAlto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) CFO Nicholas Conrad Smith purchased 6,150 shares of the stock in a transaction dated Thursday, March 28th. The shares were purchased at an average cost of $16.36 per share, for a total transaction of $100,614.00. Following the transaction, the chief financial officer now owns 26,866 shares in the company, valued at approximately $439,527.76. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alto Neuroscience on Strong Pipeline and Solid FinancialsMarch 25, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)March 25, 2024 | marketbeat.comStifel Nicolaus Reaffirms "Buy" Rating for Alto Neuroscience (NYSE:ANRO)Stifel Nicolaus reissued a "buy" rating and set a $32.00 price target on shares of Alto Neuroscience in a research report on Monday.March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed: Alto Neuroscience’s Promising Clinical Trials Signal Market PotentialMarch 21, 2024 | businesswire.comAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 11, 2024 | finance.yahoo.comAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsMarch 7, 2024 | finance.yahoo.comAlto Neuroscience to Participate in Upcoming Investor ConferencesFebruary 29, 2024 | marketbeat.comWilliam Blair Comments on Alto Neuroscience, Inc.'s FY2023 Earnings (NYSE:ANRO)Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at William Blair issued their FY2023 EPS estimates for Alto Neuroscience in a research note issued to investors on Tuesday, February 27th. William Blair analyst M. Minter forecasts that the company will earn ($11.78) per share forFebruary 27, 2024 | uk.investing.comAnalysts bullish on Alto NeuroscienceFebruary 27, 2024 | msn.comStifel, Baird, Jefferies bullish on Alto Neuroscience, cite upcoming dataFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alto Neuroscience Amid Promising Precision Neuropsychiatric TreatmentsFebruary 27, 2024 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Now Covered by William BlairWilliam Blair began coverage on Alto Neuroscience in a research report on Tuesday. They issued an "outperform" rating for the company.February 27, 2024 | businesswire.comAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare ConferenceFebruary 13, 2024 | morningstar.comAlto Neuroscience Inc ANROFebruary 13, 2024 | uk.investing.comAlto Neuroscience Inc (ANRO)February 13, 2024 | cnn.comAlto Neuroscience, Inc.February 12, 2024 | finance.yahoo.comAlto Neuroscience, Inc. (ANRO)February 12, 2024 | finance.yahoo.comAlto Neuroscience Announces Pricing of Upsized Initial Public OfferingFebruary 12, 2024 | finance.yahoo.comAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address On June 10, Nvidia makes its next big move (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. ANRO Media Mentions By Week ANRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANRO News Sentiment▼0.000.78▲Average Medical News Sentiment ANRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANRO Articles This Week▼12▲ANRO Articles Average Week Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MannKind News Today Calliditas Therapeutics AB (publ) News Today Day One Biopharmaceuticals News Today AbCellera Biologics News Today Mirum Pharmaceuticals News Today Prothena News Today Collegium Pharmaceutical News Today Enliven Therapeutics News Today Cassava Sciences News Today Arcturus Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANRO) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.